GLPG Stock Overview
A biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Galapagos NV Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €23.50 |
| 52 Week High | €39.00 |
| 52 Week Low | €23.02 |
| Beta | 0.058 |
| 11 Month Change | 1.38% |
| 3 Month Change | -13.73% |
| 1 Year Change | -36.95% |
| 33 Year Change | -53.67% |
| 5 Year Change | -84.99% |
| Change since IPO | 46.88% |
Recent News & Updates
Recent updates
Galapagos NV (AMS:GLPG) Analysts Are More Bearish Than They Used To Be
Apr 19
Galapagos NV's (AMS:GLPG) Shares Lagging The Industry But So Is The Business
Jan 03Lacklustre Performance Is Driving Galapagos NV's (AMS:GLPG) Low P/S
Jul 18€41.78: That's What Analysts Think Galapagos NV (AMS:GLPG) Is Worth After Its Latest Results
May 06Here's Why We're Not Too Worried About Galapagos' (AMS:GLPG) Cash Burn Situation
Mar 29Shareholder Returns
| GLPG | NL Biotechs | NL Market | |
|---|---|---|---|
| 7D | -7.1% | -1.3% | -4.2% |
| 1Y | -36.9% | -3.0% | 5.3% |
Return vs Industry: GLPG underperformed the Dutch Biotechs industry which returned -3% over the past year.
Return vs Market: GLPG underperformed the Dutch Market which returned 5.3% over the past year.
Price Volatility
| GLPG volatility | |
|---|---|
| GLPG Average Weekly Movement | 3.3% |
| Biotechs Industry Average Movement | 7.4% |
| Market Average Movement | 3.6% |
| 10% most volatile stocks in NL Market | 7.0% |
| 10% least volatile stocks in NL Market | 2.4% |
Stable Share Price: GLPG has not had significant price volatility in the past 3 months.
Volatility Over Time: GLPG's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 683 | Paul Stoffels | www.glpg.com |
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company’s pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l.
Galapagos NV Fundamentals Summary
| GLPG fundamental statistics | |
|---|---|
| Market cap | €1.55b |
| Earnings (TTM) | €31.50m |
| Revenue (TTM) | €261.40m |
49.2x
P/E Ratio5.9x
P/S RatioIs GLPG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GLPG income statement (TTM) | |
|---|---|
| Revenue | €261.40m |
| Cost of Revenue | €296.89m |
| Gross Profit | -€35.48m |
| Other Expenses | -€66.98m |
| Earnings | €31.50m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Oct 30, 2024
| Earnings per share (EPS) | 0.48 |
| Gross Margin | -13.57% |
| Net Profit Margin | 12.05% |
| Debt/Equity Ratio | 0% |
How did GLPG perform over the long term?
See historical performance and comparison